Inhibiting HIF-2α can reverse right heart failure and pulmonary arterial hypertension [31], while deleting cardiomyocyte-specific HIF-2α can worsen myocardial ischemia-reperfusion injury [32]. This evidence concerns the gene EPAS1 and pulmonary arterial hypertension.